• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Crohn’s disease (CD) - Articles and news items

patent-redhill-biopharma

RedHill Biopharma receives patent approval for MS drug

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

A first Phase III study with RHB-104 for the treatment of Crohn’s disease is currently ongoing, as well as a Phase IIa proof-of-concept study for the treatment of MS…

Takeda & TiGenix announce Perianal Fistulas trial treatment results in patients with Crohn's disease

Takeda & TiGenix announce Perianal Fistulas trial treatment results for Crohn’s disease

Industry news / 2 August 2016 / Takeda Pharmaceutical Company Limited / TiGenix NV

Takeda and TiGenix announce that the results of the Phase 3 ADMIRE-CD trial investigating Cx601 have been published. Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease…

sb5

Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5

Industry news / 18 July 2016 / Victoria White, Digital Content Producer

At an estimated $4billion a year, the reference product, Humira, is among the European Union’s largest single drug expenditures…

cx601

Takeda enters into licensing agreement for ex-US rights to Cx601

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in Crohn’s disease…

flixabi

Infliximab biosimilar Flixabi approved in the EU

Industry news / 31 May 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade…

crohn's disease

Clinical remission data for Stelara in Crohn’s disease presented at DDW

Industry news / 25 May 2016 / Victoria White, Digital Content Producer

Data shows that a greater proportion of adult patients with Crohn’s disease receiving Stelara SC maintenance therapy were in clinical remission at one year…

inflectra

FDA approves Inflectra (biosimilar infliximab) in the US

Industry news / 6 April 2016 / Victoria White, Digital Content Producer

With this approval, Celltrion’s Inflectra becomes the first biosimilar monoclonal antibody (mAb) medication to receive approval in the US…

BI 655066

AbbVie and Boehringer Ingelheim collaborate on BI 655066

Industry news / 7 March 2016 / Victoria White

BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma…

stem cell therapy

Stem cell therapy does not provide significant improvement in Crohn’s disease

Industry news / 17 December 2015 / Victoria White

A clinical trial to test the effectiveness of a stem cell therapy among adults with difficult to treat Crohn’s disease has found it is not significantly better than conventional treatment in producing sustained disease remission after one year…

GED-0301-crohn's-disease

TxCell reacquires full rights to Ovasave from Trizell

Industry news / 3 December 2015 / Victoria White

TxCell has agreed with Trizell to terminate the collaboration, option, development and license agreement concerning TxCell’s lead product Ovasave…

stelara

Janssen seeks approval of Stelara for Crohn’s disease

Industry news / 30 November 2015 / Victoria White

Stelara (ustekinumab), approved for the treatment of plaque psoriasis and active psoriatic arthritis in many countries, is a human monoclonal antibody that targets interleukin (IL)-12 and IL-23 cytokines…

stelara

Stelara induces clinical remission in Crohn’s disease in Phase 3 trial

Industry news / 20 October 2015 / Victoria White

The Phase 3 study achieved its primary endpoint with Stelara treatment groups demonstrating significantly higher rates of clinical response at week 6…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +